AZN:NYSE
AstraZeneca PLC (US)
$168.10
arrow_upward
+1.12%(+1.87) 1D
$168.68
arrow_upward
+0.35% (+0.58)todayPre-market
Closed: Sep 21, 4:00:03 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AZN...
Open
$168.45
High
$169.00
Low
$167.11
Mkt. cap
262.82B
Avg. vol.
3.33M
Volume
1.82K
Dividend
1.92%
Quarterly dividend
$0.81
Ex-dividend date
Aug 6, 2026
P/E ratio
25.13
52-wk high
$212.71
52-wk low
$72.90
EPS
$6.69
Beta
0.28
Shares outstanding
1.55B
No. of employees
96K
Open
$168.45
High
$169.00
Low
$167.11
Mkt. cap
262.82B
Avg. vol.
3.33M
Volume
1.82K
Dividend
1.92%
Quarterly dividend
$0.81
Ex-dividend date
Aug 6, 2026
P/E ratio
25.13
52-wk high
$212.71
52-wk low
$72.90
EPS
$6.69
Beta
0.28
Shares outstanding
1.55B
No. of employees
96K
News stories
From web sources and news partners
AD HOC NEWS
·
4 hours ago
AstraZeneca stock heads into the open after a 0.32 percent drop
Yahoo Finance
·
7 hours ago
AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England
Zacks
·
11 hours ago
Astrazeneca (AZN) Ascends But Remains Behind Market: Some Facts to Note
Zacks
·
15 hours ago
AZN's Klygefa Gets CHMP Nod for Generalised Myasthenia Gravis in EU
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About AstraZeneca PLC (US)
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorPharmaceutical industry
Websiteastrazeneca.com